Inclusion Criteria:

- Histopathologically confirmed newly diagnosed glioblastoma multiforme with WHO grade
IV.

- Histological diagnosis must be made locally after biopsy or neurosurgical tumor
resection.

- Four or more unstained tissue sections or a paraffin block must be provided to the
Pathological Judgment Committee as tissue specimens.

- Initial surgery/biopsy at diagnosis performed <=6 weeks (42 days) prior to treatment
with temozolomide.

- Age: >=18 and <=70 years.

- ECOG performance status <=2.

- Stable, non-increasing dose of corticosteroids over the 14 days prior to treatment
with temozolomide.

- No prior chemotherapy or radiotherapy.

- Laboratory test values obtained within 14 days before initiation of administration of
temozolomide must satisfy the following criteria:

- absolute neutrophil count >= 1500/mm^3;

- platelet count >= 100,000/mm^3;

- serum creatinine <=1.5 times the upper limit of laboratory normal;

- total bilirubin <=1.5 times the upper limit of laboratory normal;

- glutamic oxaloacetic transaminase or glutamic pyruvic transaminase <2.5 times
the upper limit of laboratory normal;

- alkaline phosphatase < 2.5 times the upper limit of laboratory normal.

- Absence of pathological conditions that interfere with taking oral drugs.

- Contraception during the study period (from informed consent to the day of the last
observation/examination of this study) is required in sexually active, potentially
fertile patients, regardless of sex, under the supervision of the investigator or
sub-investigator.

- The investigator and/or subinvestigator must judge that life expectancy is 12 weeks
or more.

- Patients may be included regardless of sex or inpatient/outpatient.

Exclusion Criteria:

- Extensively disseminated glioblastoma multiforme.

- Severe disorders in the heart, liver, kidney, blood, etc.

- Presence of previous or concurrent malignancies at other sites with the exception of
surgically cured carcinoma in-situ of the cervix and non melanoma skin cancer.

- Women who are pregnant or lactating.

- Women who may be pregnant or who could become pregnant and do not adopt contraception
method(s).

- Participation in another clinical study within 6 weeks prior to the initiation of
administration of temozolomide.

- Subjects who the investigator and/or subinvestigator judged inappropriate to
participate in the study.